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1 |  INTRODUCTION
Horses are predisposed to corneal trauma due to their lateral 
globe position, exposed corneas, prey behavior, and, often, 
their living environment.1-3 Potentially pathogenic bacte-
rial and fungal organisms, for example, Streptococcus spp., 
Staphylococcus spp., Pseudomonas spp., Enterobacteriaceae, 
Aspergillus spp., and Penicillium spp., are ubiquitous in the 
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Objective: To retrospectively describe laboratory findings, treatment, and outcome 
associated with equine infectious keratitis in Finland.
Animals and procedures: Medical records of horses diagnosed with infectious 
keratitis in University of Helsinki Equine Hospital from January 2007 to June 2018 
were reviewed.
Results: Forty‐seven cases were included. Keratomycosis was diagnosed in 27 eyes 
and bacterial keratitis in 20 eyes. Aspergillus flavus was the most frequent fungal 
isolate (9/17, 53%), followed by Cylindrocarpon sp. (3/17, 18%) and Aspergillus 
fumigatus (2/17, 12%). Susceptibility was tested for 10/11 Aspergillus sp. isolates; all 
were susceptible to voriconazole while only two were susceptible to amphotericin B. 
Cylindrocarpon sp. isolates were resistant to both agents. Streptococcus equi subsp. 
zooepidemicus was the most frequent bacterial isolate (9/19, 47%), followed by other 
streptococci (4/19, 21%). All 13 Streptococcus sp. isolates were susceptible to peni-
cillin, and all tested isolates (n = 11) were also susceptible to chloramphenicol. Mean 
duration of medical treatment was longer in fungal keratitis (38 days) than in bacte-
rial keratitis (25 days) (P < .001). Twenty‐six of the eyes underwent globe‐sparing 
surgery in addition to medical therapy. Recovery was achieved in 66% (31/47) of all 
cases and in 59% (16/27) and 75% (15/20) (P = .264) of cases with keratomycosis 
and bacterial keratitis, respectively.
Conclusions: Although Aspergillus sp. and S  zooepidemicus were the most fre-
quently encountered isolates, cytology, culture, and susceptibility testing are essen-
tial to differentiate bacterial and fungal keratitis and guide the clinician to choose the 
most efficient treatment.
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equine living environment in dust and vegetative material, 
and thus, horses are considered more susceptible to corneal 
infections than other species.1,2,4,5 Infectious corneal disease 
is a vision‐threatening process with a potential risk of loss of 
the globe; it thus requires appropriate, aggressive interven-
tion.1,2,6 Corneal infections can be classified as ulcerative or 
nonulcerative, the former being more common.1-3 Most often, 
the corneal infection originates from contamination of a trau-
matic ulcer, or the access of microorganisms from the envi-
ronment or the ocular microflora into the corneal stroma by 
traumatic micropuncture. However, epithelial nonulcerative 
keratomycosis associated with precorneal tear film instability 
occurs without predisposing corneal injury, and thus, a cor-
nea infected with fungi may not in all cases initially stain with 
fluorescein.1,2,7,8 Equine ocular normal microflora consists of 
a mixture of opportunistic Gram‐positive and Gram‐negative 
bacteria as well as fungal organisms.1,9-14 Regional and geo-
graphical differences in the susceptibility patterns of both 
normal equine conjunctival microflora and organisms associ-
ated with disease exist.9-15 Topical antimicrobial and steroidal 
medications are considered a predisposing factor, particularly 
for corneal fungal infections, due to the altered microenviron-
ment and suppressed immune response.1,2,6,12,16,17
Equine fungal keratitis is a common condition, especially 
in warm and humid climate regions.1,2,8,16,18,19 However, sev-
eral recent publications have raised awareness of its preva-
lence also in geographic areas of more temperate climates, 
including European countries, particularly during summer 
and autumn months with sufficient temperature and precip-
itation.6,15,19-24 Finland is mostly situated in the north tem-
perate zone with a subarctic climate. Due to the latitude of 
the country, the southernmost parts have a cool summer and 
humid continental climate. The University of Helsinki Equine 
Hospital is the only referral hospital in Finland providing 
emergency service around‐the‐clock for equine patients, and 
thus, it receives patients from the entire country. To the au-
thors' knowledge, only a single case report25 has previously 
been published addressing equine corneal infections in the 
Nordic countries. The purpose of this study was to retrospec-
tively describe diagnosis, associated pathogens, possible pre-
disposing factors, treatment, and overall success rates of both 
bacterial and fungal keratitis in different climate conditions 
than those reported in previous publications internationally, 
thus raising awareness of the disease and contributing to the 
direction of future research.
2 |  MATERIALS AND METHODS
Medical records of horses diagnosed with fungal or bacterial 
keratitis from January 2007 to June 2018 were extracted from 
the University of Helsinki Equine Hospital patient database 
(Provet Net, Finnish Net Solutions Oy). All cases included 
in the study were reported to present with clinical signs and 
response to treatment compatible with infectious keratitis. 
Cases with fungal hyphae or bacteria detected in corneal 
cytology and/or histology samples or significant fungal or 
bacterial isolates yielded in culture or both were included 
and subsequently classified into fungal or bacterial keratitis. 
Seven cases with diagnosis of bacterial keratitis based on 
clinical findings and neutrophilia without indications of the 
causative pathogen in cytology and with negative or miss-
ing culture result were discarded from the material. Twenty‐
two cases diagnosed with corneal stromal abscess without a 
representative cytology, biopsy, or culture sample or with 
the absence of pathogens in the samples obtained were also 
discarded.
Each case was individually reviewed and the following 
information collected: age, sex, breed, eye affected, date of 
admission, topical medication prior to presentation, clinical 
diagnosis, findings in cytology and/or histopathology, results 
of bacterial and/or fungal culture and susceptibility testing, 
medications administered, surgical procedures performed, 
duration of treatment, and outcome. Recovery was defined 
as a spared visual, cosmetically acceptable, and comfortable 
globe at the time of the final control examination. The season 
of presentation was determined based on the month of initial 
presentation in the hospital. Seasons were classified as spring 
(March, April, May), summer (June, July, August), autumn 
(September, October, November), and winter (December, 
January, February).
Corneal samples were routinely collected under sedation 
and often using periocular nerve blocks. Specimens for bac-
terial or fungal culture were obtained by first administering 
one drop of oxybuprocaine or tetracaine onto the cornea of 
the affected eye and then brushing the affected area with 
a cotton‐tipped transport swab (M40 Transystem, Copan 
Diagnostics Inc). Cytology specimens were obtained by 
brushing the affected corneal area with a sterile swab or cy-
tobrush (Cytobrush Plus, Medscan AB), or gently scraping 
with the blunt tip of the scalpel blade. Collected material was 
then rolled or spread onto a glass slide.
Cytology samples were routinely stained with May‐
Grünwald Giemsa and/or occasionally with Diff‐Quik or 
Gram's stain. Surgical specimens for histopathological exam-
ination were fixed in 10% formalin (containing ~4% formal-
dehyde), cut, and stained with hematoxylin and eosin (HE) 
and periodic acid–schiff (PAS).
Transport swabs for bacterial and fungal culture were re-
ferred to the Finnish Food Authority until summer 2010, after 
which bacterial specimens were referred to the Laboratory of 
Clinical Microbiology of the Faculty of Veterinary Medicine, 
University of Helsinki, and fungal swabs were referred to 
the Hospital District of Helsinki and Uusimaa Laboratory 
(HUSLAB). Aerobic bacterial culture was performed by plat-
ing the swab samples onto tryptic soy agar with 5% sheep 
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blood (TSA‐SB, Oxoid Ltd.), chocolate agar (Oxoid Ltd.), 
and Dixon agar (Tammertutkan Maljat OY). Five percent 
CO2 was added to the atmosphere of TSA‐SB and chocolate 
agar, and they were incubated for up to four days at 35 ± 2°C. 
Dixon agar was incubated at 35 ± 2°C in regular atmosphere. 
Bacterial isolates were identified using biochemical methods26 
until January 2016, after which isolates were identified using 
matrix‐assisted light desorption/ionization‐time‐of‐flight 
(MALDI‐TOF) mass spectrometry (microflex LT, Bruker 
GmBH). Susceptibility testing was performed according to 
the Clinical & Laboratory Standards Institute (CLSI) guide-
lines using systemic breakpoints, as specific breakpoints for 
topical antimicrobials are not available.27 Antimicrobials to 
which the bacterial species was intrinsically resistant were 
not tested, with the exception of fusidic acid and streptococci. 
For the purpose of reporting, intermediate and resistant results 
were pooled as “nonsusceptible.” Antimicrobials investigated 
were chosen based on the bacterial species isolated and topical 
ocular preparation availability.
For fungal culture, specimens were cultured onto 
Sabouraud glucose plates (Lab M Ltd., Lancashire, UK) at 28 
and 37°C for up to 4 weeks. Plates were checked for growth 
daily. Fungal growth was transferred to potato dextrose 
plates (Difco™, VWR International) for easier identifica-
tion of spore structures and incubated in the same conditions. 
Antifungal susceptibility testing was performed using gradi-
ent diffusion strips (ETEST®, bioMérieux SA) on Roswell 
Park Memorial Institute (RPMI, VWR International Oy and 
Sigma‐Aldrich Finland Oy) agar at 37°C. For filamentous 
fungi, susceptibility was tested to amphotericin B, itracon-
azole, posaconazole, and voriconazole. For yeast‐like fungi, 
susceptibility was tested to amphotericin B, voriconazole, 
caspofungin, and fluconazole. Minimal inhibitory concentra-
tions (MICs) were interpreted using breakpoints provided by 
European Committee on Antimicrobial Susceptibility Testing 
(EUCAST).28 When specific breakpoints were lacking, the 
MICs were interpreted based on the most conservative break-
point available for the fungal group observed.
Descriptive statistics of the study variables were calcu-
lated by diagnosis of fungal or bacterial keratitis. To iden-
tify risk factors, the associations of the studied variables with 
fungal keratitis were investigated with univariable logistic 
regression models. The effect of the duration of symptoms 
prior to referral on the duration of medical treatment after 
diagnosis was investigated using linear regression analysis. 
Odds ratios (ORs) with 95% profile likelihood confidence 
intervals (CIs) were calculated to quantify the results. P val-
ues < .05 were considered significant. All statistical analyses 
were done using IBM SPSS Statistics v. 25 (IBM Corp.).
3 |  RESULTS
During the observed time period of 11.5 years, a total of 47 
cases of unilateral corneal infections were found to match the 
inclusion criteria. Twenty‐two of the horses were mares, 19 
were geldings, and 6 were stallions. The majority of horses 
were warmbloods (n = 29, 62%), followed by Standardbreds 
(n  =  7, 15%). Other breeds represented were Finnhorses 
(n = 3), Cross‐bred ponies (n = 3), and one each of Quarter 
horse, Icelandic horse, Welsh pony, Shetland pony, and 
American Miniature horse. The age of the horses varied from 
3 months to 25 years, with an average age of 9 years and a 
median age of 8 years.
The right eye was affected in 24 cases and the left in 23 
cases. Only six cases (13%) were first opinion cases, the rest 
were referrals. In 39 cases (83%), the owner and/or refer-
ring veterinarian reported recent topical antimicrobial med-
ication (duration of more than one day) of the affected eye, 
most often chloramphenicol (n = 28, 60%). Previous topical 
steroid medication (with last dose given within a week) was 
reported in 12 cases (26%). Twenty‐seven cases (57%) were 
diagnosed with fungal keratitis, of which 4 had a stromal ab-
scess and 23 an ulcerative keratomycosis. In 18 of 27 cases 
of fungal keratitis, the patient was male (14 geldings and 4 
stallions), and thus, male horses were significantly (P = .035, 
F I G U R E  1  Seasonal distribution 
of equine cases diagnosed with fungal or 
bacterial keratitis in Finland from January 
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OR 3.70, CI95% 1.10‐12.5) more likely to have fungal kerati-
tis than mares. Bacterial keratitis was diagnosed in 20 eyes 
(43%); two were stromal abscesses and 18 ulcerative lesions. 
Seasonal distribution of cases is presented in Figure 1, and a 
strong tendency of infectious keratitis to present during sum-
mer (n = 20, 43%) and autumn (n = 16, 34%) months was 
found. However, the season (compared to winter) did not im-
pact the diagnosis (bacterial vs. fungal) (spring P = .624, OR 
2.00, CI95% 0.13‐31.98; summer P =  .250, OR 4.00, CI95% 
0.38‐42.37; autumn P =  .355, OR 3.11, CI95% 0.28‐34.42). 
Distribution of cases over the study period is presented in 
Figure 2.
3.1 | Cytology, histopathology, isolated 
pathogens, and susceptibility patterns
Bacterial (n = 35) and/or fungal (n = 27) culture was per-
formed in 39 cases (83%). Of these, 19 yielded positive bac-
terial culture and 16 positive fungal culture, with one being 
positive for both. In one case, based on the pathologist's re-
port, a primary fungal and secondary bacterial infection was 
diagnosed by histopathology, but only the bacterial culture 
result was available. A pathogen was identified by culture 
in 72% (n = 34) of the cases. In 26 cases, a unanimous cul-
ture and cytology and/or histopathology result was available. 
Thirteen cases (28%) were diagnosed solely based on find-
ings in cytology or histopathology. Observation of fungal hy-
phae in cytology was strongly correlated (P = .004 OR 45.5, 
CI95% 3.48‐594.68) with a positive result in fungal culture.
Bacterial isolates diagnosed are presented in Table 1. The 
most frequent isolate was Streptococcus equi subsp. zooepi-
demicus (9/19, 47%). Susceptibility results were available for 
18/19 (95%) bacterial isolates (Table 2). Results were missing 
for a single case of Corynebacterium sp. isolate. All tested 
bacterial isolates were susceptible to penicillin G (n = 16), 
chloramphenicol (n = 12), gentamycin (n = 7), and trimetho-
prim sulfadiazine (n = 15). All of the tested S zooepidemicus 
(n = 6) and Streptococcus sp. isolates (n = 4) were resistant 
to fusidic acid, as expected. Susceptibility to tetracycline was 
variable, as 4/7 S zooepidemicus and 2/2 Streptococcus sp. 
isolates were susceptible.
Of the 17 fungal isolates, the most frequently found organ-
ism was Aspergillus flavus (53%) (Table 3). In one case, both 
A flavus and Cryptococcus laurentii were isolated. Among the 
12 cases where topical steroid medication had been adminis-
tered prior to presentation, seven horses were diagnosed with 
fungal keratitis and five with bacterial keratitis. A flavus was 
isolated from three patients with fungal keratitis and previous 
steroid treatment. The other two yielded Lichtheimia corym-
bifera or Paecilomyces sp. In two of the cases, fungal culture 
was not available. Previous steroid medication was not found to 
have a significant influence on the type of causative pathogen 
(bacterial vs fungal, P =  .883, OR 0.91, CI95% 0.24‐3.43) or 
the outcome (P = .902, OR 1.09, CI95% 0.27‐4.39). Eyes previ-
ously treated with chloramphenicol (n = 28) were less likely to 
be diagnosed with bacterial keratitis (P = .003, OR 0.13, CI95% 
0.03‐0.49). However, a similar effect was not seen for topical 
antimicrobials as a whole (P = .057, OR 0.19, CI95% 0.03‐1.05). 
Topical antimicrobial treatment prior to referral did not influ-
ence the outcome (P = .821, OR 1.20, CI95% 0.253‐5.82). Nor 
did previous steroid (P = .747, OR 1.24, CI95% 0.33‐4.71) or 
F I G U R E  2  Annual distribution of 
equine cases diagnosed with fungal or 
bacterial keratitis in Finland form January 
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antimicrobial treatment (P = .075, OR 4.80, CI95% 0.86‐27.95) 
increase the odds for globe‐sparing surgery.
Susceptibility was tested for 88% (15/17) of isolates: 14 
filamentous fungal isolates and a single isolate of yeast‐
like fungi Cryptococcus laurentii. The susceptibility of 
Aspergillus flavus and Cylindrocarpon sp. is shown in 
Table 4. Susceptibility results were not available for single 
isolates of Lichtheimia corymbifera and A  fumigatus. All 
tested A flavus isolates and the one A fumigatus isolate (MIC 
0.19 mg/L) were susceptible to voriconazole. Only one of the 
nine A flavus isolates and the single isolate of A fumigatus 
(MIC 1 mg/L) were sensitive to amphotericin B. Six of the 
nine A flavus isolates and the one A fumigatus isolate (MIC 
0.75 mg/L) showed sensitivity to itraconazole. None of the 
A flavus isolates showed sensitivity to posaconazole, but the 
one A fumigatus (MIC 0.125 mg/L) did.
Neither EUCAST nor CLSI has yet provided clini-
cal breakpoints for interpreting MICs for Fusarium sp. or 
Paecilomyces sp. When interpreted based on MIC breakpoints 
given for A fumigatus (Table 5), the single Paecilomyces sp. 
isolate (MIC in mg/L: amphotericin B 24; itraconazole 2; po-
saconazole 0.5; voriconazole 32) was resistant to all tested 
antifungal agents. All three Cylindrocarpon sp. isolates were 
resistant to all tested antifungal agents, when interpreted 
using MIC breakpoints for A  fumigatus (Table 5) and se-
quence‐based in vitro MIC profile for C lichenicola/F lichen-
icola.29 The Cryptococcus laurentii isolate showed sensitivity 
only to amphotericin B (MIC in mg/L: amphotericin B 0.047; 
voriconazole 0.125; caspofungin > 32; fluconazole 6).
3.2 | Treatment and outcome
The mean duration and median duration of symptoms prior to 
referral were 10 and 7 days, respectively. In cases with fungal 
keratitis, the duration was significantly (P = .018, OR 8.85, 
CI95% 0.80‐0.98) longer, mean 13 days, than in cases of bacte-
rial keratitis, mean 6.5 days. Two of the 47 cases of infectious 
keratitis underwent enucleation on the day of presentation, 
and thus, 45 patients received medical treatment for the oph-
thalmic condition. Systemic nonsteroidal anti‐inflammatory 
drugs, most frequently flunixin meglumine, were standardly 
used. Omeprazole and/or sucralfate was administered when 
required based on the clinician's judgment. All cases going 
through globe‐sparing surgery received intravenous penicil-
lin G 22 000 IU/kg and gentamicin 6.6 mg/kg. Other topical, 
oral, and subconjunctival medications used, their dosages, 
and the frequency of administration are listed in Table 6. In 
the majority of cases, topical ocular medication was adminis-
tered via the subpalpebral lavage system.
Recovery was achieved in 66% (31/47) of cases with an 
average duration of topical medication of 32 days. The period 
of topical medication was significantly (P = .007, OR 1.15, 
CI95% 1.04‐1.27) longer (mean 38 and median 39.5 days) for 
fungal keratitis than for bacterial keratitis (mean and me-
dian 25 days). Twenty‐six of the 47 eyes (55%) underwent 
surgery to save the globe, two of them twice. Ten (38%) of 
these suffered from bacterial keratitis and 16 (62%) from 
fungal keratitis. The odds for having globe‐sparing surgery 
did not differ significantly between the groups of bacterial 
and fungal keratitis (P =  .529, OR 1.46, CI95% 0.45‐4.66). 
Keratectomy and conjunctival graft was performed in 23 sur-
geries (22 cases) and keratectomy only in five surgeries (five 
cases). Twenty‐three of 26 eyes (88%) treated surgically re-
covered. The period of medical treatment was significantly 
longer (P = .012, OR 1.28, CI95% 1.06‐1.56) in cases having 
globe‐sparing surgery (mean 36 days) than in cases treated 
medically (mean 20 days). The duration of symptoms prior 
to referral did not have a significant impact on the outcome 
T A B L E  2  Antimicrobial susceptibility results of Streptococcus equi subsp. zooepidemicus isolates diagnosed in cases of equine bacterial 
keratitis in Finland from January 2007 to June 2018
N PCG TMPS ERY CLI TC CHL CIP FUS GEN MOX
Resistant 0 0 0 2 3 0 3 6 0 0
Susceptible 9 8 3 1 4 8 2 0 2 1
Total 9 8 3 3 7 8 5 6 2 1
% Susceptible 100.0 100.0 100.0 33.3 57.1 100.0 40.0 0.0 100.0 100.0
Abbreviations: CHL, chloramphenicol; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; FUS, fusidic acid; GEN, gentamicin; MOX, moxifloxacin; PCG, 
penicillin G; TC, tetracycline; TMPS, trimethoprim sulfadiazine.
T A B L E  3  Fungal organisms isolated from cases of equine fungal 
keratitis in Finland from January 2007 to June 2018
Organism No. of isolates
Aspergillus flavus 9
Aspergillus fumigatus 2
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(P = .755, OR 0.99, CI95% 0.93‐1.06) or the duration of top-
ical medication (F(1, 29) = 2.258, P =  .144, R2 = 0.072). 
The season (compared to winter) did not impact the out-
come (spring P = .819, OR 1.33, CI95% 0.11‐15.70; summer 
P = .835, OR 1.23, CI95% 0.17‐9.25; autumn P = .718, OR 
1.47, CI95% 0.18‐11.72).
Fifteen of 20 eyes (75%) with bacterial keratitis recov-
ered. One horse was euthanized at the owner's request, and 
four horses were enucleated for prognostic and/or finan-
cial reasons. Ten eyes with bacterial keratitis were treated 
surgically and nine of these (90%) recovered. Surgical 
treatment did not statistically influence the outcome in 
bacterial keratitis (P = .147, OR 6.00, CI95% 0.53‐67.65). 
Sixteen of 27 eyes (59%) with fungal keratitis recovered. 
One horse died during recovery from general anesthesia 
performed for globe‐sparing surgery, one horse was euth-
anized at the owner's request, and nine horses were enu-
cleated for prognostic and/or financial reasons. Sixteen 
eyes with fungal keratitis were treated surgically and 
14 of these (88%) recovered. Surgical treatment signifi-
cantly (P = .002, OR 31.50, CI95% 3.74‐265.43) increased 
the odds for recovery in fungal keratitis cases (88% vs 
18%). The diagnosis (fungal vs bacterial) did not have a 
significant impact on the outcome (P  =  .264, OR 2.06, 
CI95% 0.58‐7.35).
4 |  DISCUSSION
Recent findings regarding the incidence, causative micro-
organisms, and susceptibility patterns of equine infectious 
keratitis have raised new questions and increased the need 
for knowledge from different geographical locations to facili-
tate targeted, efficient treatment, while concurrently avoiding 
misuse of antimicrobials. To the authors' knowledge, this is 
the first comprehensive report discussing equine infectious 
keratitis in Northern Europe.
A mixed infection of bacteria and fungi was diagnosed 
in only 4% of cases (n  =  2), far less frequently than the 
15%‐50% that has been previously published.6,16,24,30,31 This 
may be attributable to the high rate of previous antimicrobial 
medication or even to the antimicrobial metabolites produced 
by certain fungal species, as discussed by Sherman et al.31 
The breed distribution in our study was roughly consistent 
with the patient population at the University of Helsinki 
Equine Hospital during the observation period (data not 
shown). The median age of 8 years was quite similar to ear-
lier reports.16,20,32 Male horses were diagnosed with fungal 
keratitis significantly more often than mares, in contrast to 
other studies.6,13,16,30 The reason for this finding could not be 
identified.
Most of the patients had been referred and had received 
treatment with topical antimicrobials. Bacterial keratitis 
was diagnosed in less than half of the cases. S zooepidem-
icus was the most frequent bacterial isolate, and this was in 
agreement with previous results from Tennessee (USA) and 
Switzerland.34,35 In contrast, Pseudomonas sp. has been the 
Amphotericin B Itraconazole Posaconazole Voriconazole
Aspergillus flavus
1 1 1 0.25 0.38
2 16 1.5 0.25 0.19
3 2 0.75 0.38 0.19
4 3 1 0.25 0.5
5 1.5 1.5 0.38 0.19
6 2 0.38 0.19 0.19
7 4 1.5 0.25 0.19
8 12 1 0.19 0.125
9 3 1 0.25 0.19
Cylindrocarpon sp.
1 8 >32 >32 4
2 2 32 32 3
3 24 >32 >32 8
T A B L E  4  Minimal inhibitory 
concentrations in mg/L for Aspergillus 
flavus and Cylindrocarpon sp. isolates in 
cases of equine fungal keratitis in Finland 
from January 2007 to June 2018
T A B L E  5  Breakpoints in mg/L for interpretation of minimal 
inhibitory concentrations of Aspergillus fumigatus according to 
the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) Antifungal Clinical Breakpoint Table v. 9.028
Sensitive Resistant
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most common isolate in studies from Pennsylvania (USA), 
Florida (USA), and Japan.15,36,37 Other studies have reported 
Pseudomonas sp. to account for 5%‐12% of isolates.30,34,35 
Although Pseudomonas sp. is considered a very virulent 
corneal pathogen,2 it has been repeatedly described as an 
occasional finding in conjunctival samples from healthy 
horses.9,12,14,17 Interestingly, Pseudomonas sp. was not iso-
lated in the current data, although chloramphenicol was 
commonly used prior to referral and, in theory, has the po-
tential to alter the microbial population balance in favor of 
Pseudomonas sp.1,2,17 All tested isolates were susceptible to 
penicillin G and chloramphenicol. The result indicates good 
national status regarding antimicrobial resistance. It was in 
line with results from Switzerland,35 Japan,15 and Florida 
(USA),36 but contrary to those from Missouri (USA), 
where 67% of Gram‐positive bacteria were susceptible to 
penicillin and 48% to chloramphenicol, respectively.30 All 
tested isolates were also susceptible to trimethoprim sulfa-
diazine. Tested Streptococcus sp. isolates were moderately 
susceptible to tetracycline, comparable with results from 
Switzerland35 and Japan.15 At the University of Helsinki 
Equine Hospital, the first‐choice topical antimicrobial for 
uncomplicated corneal ulcers has been chloramphenicol 
since an ophthalmic solution containing neomycin, poly-
myxin B, and gramicidin became unavailable in 2012. With 
the current results, this protocol seems reasonable. Based 
on the resistance of streptococci to fusidic acid, it is not rec-
ommended as an empirical first‐line topical antimicrobial.
Geographical differences and climate conditions have 
been demonstrated to have an effect not only on the normal 
microbial flora of the equine conjunctival surface, but also 
on the occurrence of different fungal and bacterial patho-
gens causing infectious keratitis.9-15 In the current data, 77% 
of all cases presented during summer and autumn months. 
Many reports from the Northern Hemisphere have provided 
similar results regarding seasonal effects on the incidence 
of keratomycosis,6,20,21,31,33 albeit reports from subtropical 
Florida have repeatedly presented contradictory results.8,9,19 
It has been contemplated whether the finding is related to 
decreasing temperature and changes in humidity providing 
T A B L E  6  Medical therapy of 45 cases with infectious keratitis diagnosed in Finland from January 2007 to June 2018
Medication Route Dose No. of cases % of cases
Antimicrobial
Trimethoprim sulfadiazine Oral 30 mg/kg BID 17 38
Doxycycline Oral 10 mg/kg BID 1 2
Chloramphenicol 5 mg/mL Topical Q 2‐6 h 40 89
Ofloxacin 3 mg/mL Topical Q 2‐6 h 27 60
Tobramycin 3 mg/mL Topical Q 12 h 3 7
Neomycin‐Polymyxin B‐Gramicidin Topical Q 2‐6 h 2 4
Fusidic acid 10 mg/mL Topical Q 12 h 2 4
Moxifloxacin 5 mg/mL Topical Q 2‐6 h 1 2
Tetracycline 10 mg/mL Topical Q 8 h 1 2
Cefazolin Subconjunctival 100 mg 1 2
Antifungal
Fluconazole Oral 14 mg/kg loading dose followed 
by 5 mg/kg SID
7 16
Voriconazole 10 mg/mL Topical Q 2‐6 h 33 73
Fluconazole 2 mg/mL Topical Q 2‐6 h 13 29
Amphotericin B 2.5‐5 mg/mL Topical Q 4‐6 h 5 11
Miconazole 2% Topical Q 8 h 1 2
Amphotericin B Subconjunctival 1 mg 3 7
Proteinase inhibition
Serum Topical Q 2‐6 h 26 58
EDTA 2% Topical Q 2‐6 h 4 9
Mydriatics
Atropine 1% Topical Q 6‐24 h 45 100
Phenylephrine 10% Topical Q 8 h 1 2
Abbreviations: BID, twice a day; SID, once a day.
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favorable circumstances for fungi 16,31 or only secondary to 
changes in management such as increasing periods of time 
that the horses are kept stabled.1,2,38 The increasing effect of 
housing on the number of fungi isolated from conjunctiva of 
healthy horses has previously been noted in some studies, 
whereas others have observed few differences between the 
fungal species isolated.10,14,20 On the other hand, the majority 
of tested donkeys living outdoors in rural areas were found 
to harbor fungi in one study.11 Overall in Finland, horses are 
usually kept outdoors most of the daytime throughout the 
year. Due to the subarctic climate conditions, it is compul-
sory by law to provide a stable or a walk‐in/walkout shelter. 
Also, for example, peat moss is often used as a bedding ma-
terial, offering a suitable microenvironment for proliferation 
of filamentous fungi. Research is needed on the influence of 
different bedding materials and types of soil in the pastures 
on the fungal species isolated from both healthy and dis-
eased equine eyes.
Corneal cytology was found to predict the positive fungal 
culture well in cases of fungal keratitis, supporting previous 
results.18,39,40 Although corneal confocal microscopy has 
been described as a useful noninvasive diagnostic method in 
equine keratomycosis,41 to date it is readily available in very 
few locations. Moreover, it may take several days to isolate 
filamentous fungi in culture, rendering prompt diagnosis 
with cytology essential for recognizing the immediate need 
for antifungal therapy.42 However, culture is regarded as the 
golden standard in diagnosis of keratomycosis,40 and suscep-
tibility testing is critical for modifying the optimal treatment 
due to geographic variation in prevalence and susceptibility 
patterns of isolates.6,16,20,30,33,42-45
In the current study, Aspergillus sp. was the predom-
inant fungal species isolated (65%). A similar observation 
has been made in earlier studies of both fungal kerati-
tis and conjunctival fungal flora in healthy equids world-
wide.6,11,16,18,20,24,32,33,37,43 In global reports, Fusarium sp. 
has been the second most common fungal species isolated, 
accounting for 4%‐14% of isolates.6,24,30,32,33,43 Florida is a 
striking exception to this, with Fusarium sp. described in 
26%‐32% of the cases,16,46 and this geographical difference 
can be speculated to be linked to the warm and humid climate 
conditions, similar to the occurrence of Fusarium‐associated 
keratitis in human patients.16,19,29,46 To the authors' knowl-
edge, Fusarium sp.‐associated equine fungal keratitis has 
been reported only in a single case in Europe.24 Owing 
to recent information gathered from DNA sequencing, 
Cylidrocarpon lichenicola has been identified as a part of 
the “Fusarium solani species complex,” in contrast to other 
Cylindrocarpon species, and consequently has been re-
named as Fusarium lichenicola.47 In our data, two isolates 
of Cylidrocarpon lichennicola/Fusarium lichenicola and a 
single isolate of Cylindrocarpon sp. were reported. After the 
study period, Fusarium sp. was isolated from four additional 
cases of fungal keratitis at the University of Helsinki Equine 
Hospital. The global change in climate conditions could be 
speculated to underlie the increasing incidence of keratomy-
cosis caused by Fusarium sp., as the average temperature 
from May to August 2018 was the highest ever in Finnish 
measurement history.48 However, this subject requires ex-
tensive further investigation.
All tested Aspergillus sp. isolates were susceptible 
to voriconazole, in agreement with several previous re-
sults.6,20,44,45 Nevertheless, in a study from Mid‐Atlantic, 
USA, the authors found only 4/10 Aspergillus sp. isolates to 
be sensitive to voriconazole.49 Variable results for the sus-
ceptibility of Aspergillus sp. to itraconazole have been pre-
sented, ranging from 25% to 100%, compared with 80% in our 
study.6,43,46,49 Only 20% (n = 2) of Aspergillus isolates were 
susceptible to amphotericin B, while Ledbetter et al43 found 
86% to be susceptible. All three Cylindrocarpon sp. isolates 
were resistant to all tested agents, in contrast to Ledbetter 
et al reporting 43% of Fusarium sp. isolates to be sensitive 
to amphotericin B and Pearce et al finding voriconazole to 
be the second most effective antifungal agent for Fusarium 
sp.43,44 Itraconazole has previously been found to have poor 
efficacy for Fusarium sp.,43,46 in agreement with our results. 
Poor overall efficacy of antifungal agents can be explained 
by intrinsic resistance associated with azoles in many 
Fusarium species and a high level of cross‐resistance, and, 
on the other hand, with recently identified paths to second-
ary resistance.29 Treatment of Fusarium‐associated keratitis 
is considered a challenge also in human medicine, where 
topical natamycin, amphotericin B, and voriconazole, and 
preferably combinations of these, are currently considered 
the first‐line treatment.29 Nevertheless, frequent topical oc-
ular administration of a drug with good corneal penetration 
is likely to result in concentrations higher than the studied 
effective serum concentrations, thus achieving some clin-
ical response also in cases with pathogens expressing in 
vitro resistance.42 In the current data, all of the cases with 
Cylinrocarpon sp. were clinically challenging and under-
went globe‐sparing surgery. Two of the eyes recovered, but 
one of the horses did not survive the recovery after general 
anesthesia for corneal surgery.
Unlike natamycin, voriconazole solution suitable for oph-
thalmic use is readily available in Finland. Based on the ad-
equate effect on Aspergillus sp. in addition to evidence of 
good corneal penetration and therapeutic concentrations in 
aqueous humor with topical administration,50 voriconazole 
can be considered a primary choice for initial antifungal med-
ication in this geographic area. Before voriconazole became 
readily available in 2007‐2008, topical fluconazole or in 
some cases miconazole was used. Injectable amphotericin B 
solution is available in Finland and used in combination with 
voriconazole in selected cases, but itraconazole and posacon-
azole are currently available only as peroral formulations. In 
156 |   MUSTIKKA eT Al
contrast to oral fluconazole, itraconazole has not been proven 
to result in detectable concentrations in equine aqueous 
humor,51,52 and thus, fluconazole has been chosen as an addi-
tional therapy in challenging cases of keratomycosis, despite 
reports of poor efficacy on Aspergilllus sp.43,44,46
Inconsistent results in susceptibility testing among studies 
from different decades and geographical locations emphasize 
the importance of testing in clinical cases. However, inter-
preting MICs and comparing susceptibility results between 
different publications in the area of equine keratomycosis is 
challenging, as comprehensive information regarding clinically 
established MIC breakpoints for filamentous fungi is mostly 
unavailable. Available information, provided by CLSI and 
EUCAST, is based on the use of broth dilution susceptibility 
testing methods and systemic use of antifungal agents in human 
patients. Over 90% essential agreement has been found between 
the broth microdilution technique and ETEST® regarding sus-
ceptibility testing among various species of filamentous fungi, 
including Aspergillus sp., Fusarium sp., and Paecilomyces sp., 
with the exception of testing posaconazole among Aspergillus 
sp. (64%‐89% essential agreement).53 Using a less time‐con-
suming and technically challenging commercial agar diffusion 
test is thus acceptable, but interpretation of MICs must be done 
with caution, as the specific clinical breakpoints are lacking 
and epidemiological cut‐off values based on wild‐type distri-
bution are specific for the method used.
Median duration of topical medical treatment was 25 days 
in bacterial keratitis and 39.5 days in fungal keratitis. In pre-
vious reports, duration of treatment has been reported to be 
29‐45 days in bacterial54,55 and 37‐73 days in fungal kerati-
tis.6,16,24,33 In contrast to the results of Utter et al,37 the pe-
riod of medical treatment was significantly longer in cases 
demanding globe‐sparing surgery than in cases treated only 
medically. These differences are likely related to the sever-
ity of the disease in selected cases. In our study, a visual, 
cosmetically acceptable, comfortable globe was retained 
in 66% of all cases treated, in 75% of cases with bacterial 
keratitis, and in 59% of cases with fungal keratitis, but no 
significant difference regarding the diagnosis was found. 
The rate for favorable results was similar or somewhat lower 
than in previous reports, as Utter et al37 reported 85% and 
Andrew et al16 95% overall success rate for intact globe in 
infectious keratitis, while rates for preserving a visual globe 
in bacterial keratitis have been reported to be 73%‐76%.54,55 
For fungal keratitis, reported rates for similar success have 
been quite variable, from 50% by Galan et al24 up to 97% by 
Utter et al32 Undoubtedly, the severity of cases has a major 
effect on the success rates, and plausibly, the lack of aware-
ness of the referring veterinarian may postpone the referral, 
especially in countries with little or no previously published 
data concerning infectious keratitis, particularly fungal kera-
titis. Furthermore, the long geographic distances in Finland 
with only a single referral center with a full‐time emergency 
service probably delays the referrals. In these data, the cases 
with fungal keratitis were referred significantly later in the 
course of the disease compared to the ones with bacterial ker-
atitis. Nevertheless, the duration of symptoms prior to refer-
ral did not have a significant impact on the period of topical 
medication, or the outcome. In some cases, the owner chose 
enucleation or euthanasia for the horse for financial or per-
sonal reasons more so than for prognostic reasons.
Earlier treatment with topical or subconjunctival steroids 
has been suggested in numerous studies to predispose to fun-
gal infections and to enhance fungal replication.6,16,21,24,31,44 
In these data, 26% of the horses had received previous steroid 
medication, but the odds for them to have fungal rather than 
bacterial keratitis were not significantly higher. Although, 
overall, previous topical antimicrobial use was not associated 
with fungal keratitis, a history of topical chloramphenicol 
treatment was found to significantly increase the odds for fun-
gal keratitis. Similar findings regarding earlier antimicrobial 
treatment have been reported elsewhere, and the phenomenon 
has been thought to be related to the altered microbial popu-
lation balance by lowering the relative number of nonpatho-
genic microbes, thus also reducing the effect of antimicrobial 
enzymes secreted by selected nonpathogenic species.1,16,17,46 
The suppressing effect of chloramphenicol on natamycin‐
producing Streptomyces natalensis in the equine conjuncti-
val microenvironment is a potential factor.38,56 Nevertheless, 
concurrent antimicrobial use in fungal keratitis is deemed 
necessary, as co‐infections of fungi and bacteria occur and 
are considered difficult due to their severity.16,40 Neither pre-
vious steroid nor antimicrobial medication had an effect on 
the odds for surgical treatment or the outcome. This result 
is in agreement with previous findings,6,20,24,31,57 but even 
combined numbers of cases from different studies are too low 
for comprehensive and fully reliable evaluation of the issue. 
Sherman et al31 reported Aspergillus sp. in 6/6 horses with a 
history of steroid treatment and diagnosis of fungal kerati-
tis. In our data, Aspergillus flavus was isolated in three such 
cases, in contrast to two other isolates and two cases without 
culture result. As Aspergillus flavus was the most frequent 
fungal isolate detected and the total number of comparable 
cases was low, conclusions regarding the relation of steroids 
and the fungal species isolated cannot be drawn. In addition 
to limitations arising from the retrospective study design, the 
low number of cases and cultured isolates also limits the pos-
sibilities for other statistical analyses and does not allow in-
vestigation of the association between the cultured organism 
and the outcome. In other studies conducted to date, the spe-
cies of the fungal isolate has not been found to have an impact 
on disease severity or outcome.31,32,45 Also, it is worth noting 
that the standard culture techniques used in this study may 
not have revealed all possible pathogens, either due to pre-
vious medication administered or due to unfulfilled growth 
requirements.
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Fungal organisms are considered to be the most common 
cause of stromal abscesses, but are rarely cultured or even de-
tected in histopathology of such cases.2,18,19,58,59 In this study, 
cases of infectious keratitis were included only when the 
causative microorganism could be identified in the samples. 
Thus, only six cases diagnosed with stromal abscess were in-
cluded, and a high number of cases (n = 22) were excluded. 
For the same reason, numerous cases with clinical presenta-
tion and response to therapy suggestive of bacterial keratitis 
were excluded. The inclusion criteria create some bias in the 
study material considering the relationship of the incidence 
between bacterial and fungal keratitis in Finland. In most ex-
cluded cases of suspected bacterial keratitis with neutrophilia 
detected in cytology, bacterial culture was performed with a 
negative result. Often the cases with bacterial keratitis showed 
improvement with topical broad spectrum antimicrobial med-
ication initiated upon referral, and due to financial matters, 
topical antifungals were initiated only with an apparent suspi-
cion or proof of fungal keratitis. This leads to repeated sam-
pling occurring more often in cases with fungal keratitis with 
slow clinical response or more severe clinical presentation, 
and hence higher likelihood of identifying the causative agent.
A great annual variation could be seen in the distribution 
of the number of included cases. The reason for this is not 
known, but, for example, the impact of weather conditions 
should be further investigated. As abovementioned, the sum-
mer of 2018 was exceptionally warm in Finland, and a record 
number of 14 cases of fungal keratitis and only two cases of 
bacterial keratitis were seen in the last half of 2018 (data not 
shown). The national incidence of infectious keratitis cannot 
be reliably estimated, as only a portion of cases are referred 
to the University of Helsinki Equine Hospital.
Our findings provide new information about commonly 
cultured species and susceptibility patterns of microorgan-
isms associated with equine corneal infections in Northern 
Europe, assisting clinicians to choose the empirically most 
efficient treatment available while the culture and suscep-
tibility test results are pending. As the incidence of equine 
keratomycosis seems to be on the rise, further studies are 
warranted to gain a better understanding of the geographical 
differences in the causative pathogens.
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